Dovepress 38. LiuY, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imag- ing: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12): 2527–2537. 39. Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5): 450–460. 40. Vélez JM, Vélez JJ. The eminent need for an academic program in universities to teach nanomedicine. Int J Nanomedicine. 2011; 6:1733–1738. 41. Maojo V, García-Remesal M, de la Iglesia D, et al. Nanoinformatics: developing advanced informatics applications for nanomedicine. In: Prokop A, editor. Intracellular Delivery. Fundamental Biomedical Technologies, 5: Fundamentals and Applications. Dordrecht, Heidelberg, London, New York, NY: Springer; 2011;847–860. 42. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat Nanotechnol. 2010;5(9):671–675. 43. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57(15):2177–2202. 44. Dobson J. Gene therapy progress and prospects: magnetic nanoparticle- based gene delivery. Gene Ther. 2006;13(4):283–287. 45. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–149. 46. Daum N,Tscheka C, NeumeyerA, Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(1):52–65. 47. Wu Z, Chen K, Yildiz I, et al. Development of viral nanoparticles for efficient intracellular delivery. Nanoscale. 2012:4,3567–3576. 48. Herper M. The truly staggering cost of inventing new drugs. Forbes. February 2, 2012. Available from: http://www.forbes.com/sites/ matthewherper/2012/02/10/the-truly-staggeringcost-of-inventing-new- drugs/. Accessed April 28, 2012. 49. Iglesias J. nab-Paclitaxel (Abraxane(R)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors. Breast Cancer Res. 2009;11 Suppl 1:S21. 50. Luo C, Wang Y, Chen Q, et al. Advances of Paclitaxel formulations based on nanosystem delivery technology. Mini Rev Med Chem. 2012;12(5):434–444. 51. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16. 52. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today. 2010;5(2):143–159. 53. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem. 2005;48(19):5892–5899. 54. Park JH, von Maltzahn G, Ong LL, et al. Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv Mater. 2010;22(8):880–885. 55. Huynh L, Neale C, Pomès R, Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine. 2012;8(1):20–36. 56. Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A. 2008;105(21):7387–7392. 57. Elbaz J, Willner I. DNA origami: nanorobots grab cellular control. Nat Mater. 2012;11(4):276–277. 58. Douglas SM, Bachelet I, Church GM.A logic-gated nanorobot for targeted transport of molecular payloads. Science. 2012;335(6070):831–834. 59. Kostarelos K. Nanorobots for medicine: how close are we? Nanomedicine (Lond). 2010;5(3):341–342. 60. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int J Nanomedicine. 2010;5:803–809. 61. Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine. 2007;2(2):129–141. 62. Anguita A, Martín L, Crespo J, Tsiknakis M. An ontology-based method to solve query identifier heterogeneity in post-genomic clinical trials. Stud Health Technol Inform. 2008;136:3–8. International Journal of Nanomedicine 2012:7 Nanoinformatics: a new area of research in nanomedicine 63. Barton J, O Mathúna SC, O’Reilly S, et al. Micro and nano technology enabling ambient intelligence for P-Health. Stud Health Technol Inform. 2005;117:89–97. 64. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543–557. 65. Laurencin C, Nair LS. Nanotechnology and Tissue Engineering: The Scaffold. Boca Raton, FL: CRC Press; 2008. 66. Harper SL, Dahl JL, Maddux BL, Tanguay RL, Hutchison JE. Proactively designing nanomaterials to enhance performance and minimize hazard. Int J Nanotechnol. 2008;5(1):124–142. 67. Nyström AM, Fadeel B. Safety assessment of nanomaterials: Implications for nanomedicine. J Control Release. 2012. (Epub ahead of print). 68. Puzyn T, Leszczynska D, Leszczynski J. Toward the development of “nano- QSARs”: advances and challenges. Small. 2009;5(22): 2494–2509. 69. Harper SL, Carriere JL, Miller JM, Hutchison JE, Maddux BL, Tanguay RL. Systematic evaluation of nanomaterial toxicity: utility of standard- ized materials and rapid assays. ACS Nano. 2011;5(6): 4688–4697. 70. Thomas DG, Klaessig F, Harper SL, et al. Informatics and stan- dards for nanomedicine technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011. (Epub ahead of print). 71. Ostraat ML. The Nanomaterial Registry [presentation]. Research Triangle Park, NC: RTI International; 2011. Available from: http:// www.toxicology.org/isot/ss/nano/docs/Ostraat_guest_presentation.pdf. Accessed April 30, 2012. 72. Kulikowski CA, Kulikowski CW. Biomedical and health informatics in translational medicine. Methods Inf Med. 2009;48(1):4–10. 73. Lavik E, von Recum H. The role of nanomaterials in translational medicine. ACS Nano. 2011;5(5):3419–3424. 74. Kuiken T. Nanomedicine and ethics: is there anything new or unique? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:111–118. 75. Sandler R. Nanomedicine and nanomedical ethics. Am J Bioeth. 2009;9(10):16–17. 76. Ruping K, Sherman BW. Nanoinformatics: emerging computational tools in nano-scale research. In: Commercial tools, processes and materials, Technical Proceedings of the 2004 NSTI Nanotechnology Conference and Trade Show, Volume 3. Austin, TX: Nano Science and Technology Institute; 525–528. Available from: http://www.nsti.org/ procs/Nanotech2004v3/11/X33.06. Accessed April 30, 2012. 77. De Rosnay J. From molecular biology to biotics: the development of bio-, info- and nano-technologies. Cell Mol Biol (Noisy-le-grand). 2001;47(8):1261–1268. 78. President’s Council of Advisors on Science and Technology. Report to the President and Congress on the Third Assessment of the National Nanotechnology Initiative. Washington DC: Executive Office of the President, President’s Council of Advisors on Science and Technology; 2010. Available from: http://www.whitehouse.gov/sites/default/files/ microsites/ostp/pcast-nni-report.pdf. Accessed April 30, 2012. 79. De la Iglesia D, Harper S, Hoover MD, et al. Nanoinformatics 2020 Roadmap. Amherst, MA: National Nanomanufacturing Network; 2011. Available from: http://eprints.internano.org/607/1/Roadmap_ FINAL041311.pdf. Accessed February 28, 2012. 80. ACTION-Grid Consortium. The ACTION-Grid White Paper: Linking Biomedical Informatics, Grid Computing and Nanomedicine. ACTION- Grid Consortium; 2010. Available from: http://www.action-grid. eu/documents/ACTION-Grid%20White%20Paper.pdf. Accessed February 28, 2012. 81. National Research Council of the National Academies Committee to Develop a Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials. A Research Strategy for Envi- ronmental, Health, and Safety Aspects of Engineered Nanomaterials. Washington DC: National Academies Press; 2012. 82. Ho D, Garcia D, Ho CM. Nanomanufacturing and characterization modalities for bio-nano-informatics systems. J Nanosci Nanotechnol. 2006;6(4):875–891. 83. Baker NA, Fritts M, Guccione S, et al; National Cancer Institute, caBIG® Integrative Cancer Research Nanotechnology Working Group. Nanotechnology Informatics White Paper. Bethesda, MD: US National Institutes of Health; 2009. submit your manuscript | www.dovepress.com Dovepress 3883